EP4320441A1 — Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
Assigned to Windber Research Institute · Expires 2024-02-14 · 2y expired
What this patent protects
The present invention relates to protein markers for ER-positive-like and ER- negative-like breast cancer. Methods for differentiating ER-positive-like and ER-negative- like breast cancer in a subject having breast cancer are provided, such methods including the detection of leve…
USPTO Abstract
The present invention relates to protein markers for ER-positive-like and ER- negative-like breast cancer. Methods for differentiating ER-positive-like and ER-negative- like breast cancer in a subject having breast cancer are provided, such methods including the detection of levels of a variety of biomarkers for ER-positive-like and ER-negative-like breast cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.